Evidence map›Paper›PMID 33825685›Full record

ArticleJMIR mHealth and uHealth2021

Leprosy Screening Based on Artificial Intelligence: Development of a Cross-Platform App.

Márcio Luís Moreira De Souza, Gabriel Ayres Lopes, Alexandre Castelo Branco, Jessica K Fairley, Lucia Alves De Oliveira Fraga

Abstract read
In one paragraph

Article in JMIR mHealth and uHealth, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Interplay among differential exposure toFrontiers in immunology · 2023
    Article
  14. Article
  15. A Bibliometric Analysis of Leprosy during 2000-2021 from Web of Science Database.International journal of environmental research and public health · 2022
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Márcio Luís Moreira De SouzaMulticentre Biochemistry and Molecular Biology Program, Federal University of Juiz de Fora, Governador Valadares-MG, Brazil.ORCID 0000-0002-3710-8184
Gabriel Ayres LopesFellowship of PROEX Program/UFJF, Federal University of Juiz de Fora, Governador Valadares-MG, Brazil.ORCID 0000-0001-7505-8731
Alexandre Castelo BrancoReference Center for Endemic Diseases and Special Programs (SMS/GV), Governador Valadares-MG, Brazil.ORCID 0000-0002-9019-4261
Jessica K FairleyEmory University School of Medicine, Atlanta, GA, United States.ORCID 0000-0003-4086-9272
Lucia Alves De Oliveira FragaMulticentre Biochemistry and Molecular Biology Program, Federal University of Juiz de Fora, Governador Valadares-MG, Brazil.ORCID 0000-0002-9238-2960

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccording to the World Health Organization, achieving targets for control of leprosy by 2030 will require disease elimination and interruption of transmission at the national or regional level. India and Brazil have reported the highest leprosy burden in the last few decades, revealing the need for strategies and tools to help health professionals correctly manage and control the disease.

objectiveThe main objective of this study was to develop a cross-platform app for leprosy screening based on artificial intelligence (AI) with the goal of increasing accessibility of an accurate method of classifying leprosy treatment for health professionals, especially for communities further away from major diagnostic centers. Toward this end, we analyzed the quality of leprosy data in Brazil on the National Notifiable Diseases Information System (SINAN).

methodsLeprosy data were extracted from the SINAN database, carefully cleaned, and used to build AI decision models based on the random forest algorithm to predict operational classification in paucibacillary or multibacillary leprosy. We used Python programming language to extract and clean the data, and R programming language to train and test the AI model via cross-validation. To allow broad access, we deployed the final random forest classification model in a web app via shinyApp using data available from the Brazilian Institute of Geography and Statistics and the Department of Informatics of the Unified Health System.

resultsWe mapped the dispersion of leprosy incidence in Brazil from 2014 to 2018, and found a particularly high number of cases in central Brazil in 2014 that further increased in 2018 in the state of Mato Grosso. For some municipalities, up to 80% of cases showed some data discrepancy. Of a total of 21,047 discrepancies detected, the most common was "operational classification does not match the clinical form." After data processing, we identified a total of 77,628 cases with missing data. The sensitivity and specificity of the AI model applied for the operational classification of leprosy was 93.97% and 87.09%, respectively.

conclusionsThe proposed app was able to recognize patterns in leprosy cases registered in the SINAN database and to classify new patients with paucibacillary or multibacillary leprosy, thereby reducing the probability of incorrect assignment by health centers. The collection and notification of data on leprosy in Brazil seem to lack specific validation to increase the quality of the data for implementations via AI. The AI models implemented in this work had satisfactory accuracy across Brazilian states and could be a complementary diagnosis tool, especially in remote areas with few specialist physicians.

Indexed as

LeprosyMobile ApplicationsArtificial IntelligenceBrazilHumansIndiaappsartificial intelligenceleprosymHealthPythonRrandom forestshinyApp

Identifiers

PMID33825685
PMCPMC8060869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.